EP0040922A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
DNA sequences, recombinant DNA molecules and processes for producing polypeptides with the specificity of foot and mouth disease viral antigens
Assignee: Biogen NV
•
Filing: 1981-05-11
•
Granted: —
•
Expires: 2001-05-11
Abstract
Abstract DNA sequences, recombinant DNA molecules and hosts transformed with them which produce antigenic polypeptides of FMDV and replicate virus specific nucleotide sequences coding therefor and methods of making and using these molecules, hosts, DNA sequences and antigenic polypeptides. The DNA sequences and recombinant DNA molecules of this invention are characterized by DNA inserts that code for at least one FMDV antigenic polypeptide. In hosts capable of expressing these polypeptides, these DNA sequences and recombinant DNA molecules permit the replication and identification of virus specific nucleotide sequences and the production and identification of antigenic polypeptides and their use in compositions and methods for rendering animals resistant to FMDV at least for some period of time.
Inventors
- 👤 Peter-Hans Nofschneider
- 👤 Hans Albert Kupper
- 👤 Heinz Schaller
- 👤 Walter Keller
- 👤 Vladimir Zaslavsky
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-31 21:58
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/70; C12N15/73; C12N2770/00; C12N2770/00011; C12N2770/32011; C12N2770/32111; C12N2770/32122
Claims Analysis
Total Claims: 41
Claim 1
Independent Claim
111 words
A DNA sequence characterized in that at least a portion thereof codes for a polypeptide displaying FMDV antigenicity and being selected from the group consisting of (a) FMDV-715, FMDV-144, FMDV-1034, FMDV-1448, FMDV-1824, FMDV-1933, (b) DNA sequences which hybridize to any of the foregoing DNA sequences, (c) DNA sequences, from whatever source obtained, including natural, synthetic or semi-synthetic sources, related by mutation, including single or multiple, base substitutions, deletions, insertions and inversions to any of the foregoing DNA sequences, and (d) DNA sequences comprising sequences of codons which code for an antigenic polypeptide containing an amino acid sequence similar to those coded for by codons of any of the foregoing DNA sequences.
Claim 2
Dependent Claim
111 words
A DNA sequence characterized in that at least a portion thereof codes for a polypeptide displaying FMDV antigenicity and being selected from the group consisting of (a) FMDV-715, FMDV-144, FMDV-1034, FMDV-1448, FMDV-1824, FMDV-1933, (b) DNA sequences which hybridize to any of the foregoing DNA sequences, (c) DNA sequences, from whatever source obtained, including natural, synthetic or semi-synthetic sources, related by mutation, including single or multiple, base substitutions, deletions, insertions and inversions to any of the foregoing DNA sequences, and (d) DNA sequences comprising sequences of codons which code for an antigenic polypeptide containing an amino acid sequence similar to those coded for by codons of any of the foregoing DNA sequences.
Claim 3
Dependent Claim
116 words
A DNA sequence according to claim 1 characterized in that the DNA sequence (b) which hybridizes to at least one of the DNA sequences (a) is selected from the group consisting of (e) VP1-1, VPl-5, FMDV-1034-Bal, FMDV-1034-Bal-l(EcoRI-HindIII), (f) DNA sequences which hybridize to any of the foregoing DNA sequences, (g) DNA sequences, from whatever source obtained, including natural, synthetic or semi-synthetic sources, related by mutation, including single or multiple, base substitutions, deletions, insertions and inversions to any of the foregoing DNA sequences, and (h) DNA sequences comprising sequences of codons which code for an antigenic polypeptide containing an amino acid sequence similar to those coded for by the codons of any of the foregoing DNA sequences.
Claim 4
Dependent Claim
65 words
A DNA sequence according to claim 1 or 2 characterized in that the DNA sequences (b) or (f) which hybridizes to at least one of the DNA sequences (a) or (e) is selected from the group of (i) HaeIII fragments of FMDV-715, FMDV-144, FMDV-1034, FMDV-1448, FMDV-1824, FMDV-1933, VP1-1, VPl-5, FMDV-1034-Bal, FMDV-1034-Bal-1 (EcoRI-HindIII), and (j) DNA sequences which hybridize to any of the foregoing DNA sequences.
Claim 5
Dependent Claim
100 words
A DNA sequence according to any one of claims 1 to 3 characterized in that the DNA sequences (b), (f) or (j) which hybridizes to at least one of the DNA sequences (a), (e) or (i) is selected from the group consisting of DNA sequences coding for a single antigenic polypeptide of a single FMDV serotype, DNA sequences coding for a combination of antigenic polypeptides of a single FMDV serotype, DNA sequences coding for a combination of antigenic polypeptides of more than one FMDV serotype and DNA sequences coding for a single antigenic polypeptide for more than one FMDV serotype.
Claim 6
Dependent Claim
35 words
A DNA sequence according to claim 4 characterized in that said FMDV serotype is selected from the group consisting of FMDV type 0, A, C, SAT 1, SAT 2, SAT 3 and Asian type I.
Claim 7
Dependent Claim
43 words
A DNA sequence according to any one of claims 1 to 5 characterized in that it is selected from the group consisting of DNA sequences of the formula: and fragments and derivatives thereof, said fragments and derivatives coding for antigenic polypeptides of FMDV.
Claim 8
Dependent Claim
43 words
A DNA sequence according to any one of claims 1 to 5 characterized in that it is selected from the group consisting of DNA sequences of the formula: and fragment and derivatives thereof, said fragments and derivatives coding for antigenic polypeptides of FMDV.
Claim 9
Dependent Claim
102 words
A variant of the DNA sequence according to any one of the preceding claims characterized in that it is selected from the group consisting of FMDV-703, FMDV-331, DNA sequences which hybridize to either of the foregoing DNA sequences, DNA sequences, from whatever source obtained, including natural, synthetic or semi-synthetic sources, related by mutation, including single or multiple, base substitutions, deletions, insertions and inversions to any of the foregoing DNA sequences and DNA sequences comprising sequences of codons which code for antigenic polypeptides containing an amino acid sequence similar to those coded for by the codons of any of the foregoing DNA sequences.
Claim 10
Dependent Claim
17 words
A recombinant DNA molecule characterized by a DNA sequence according to any one of the preceding claims.
Claim 11
Dependent Claim
22 words
A recombinant DNA molecule according to claim 9, characterized in that said DNA sequence is operatively linked to an expression control sequence.
Claim 12
Dependent Claim
73 words
A recombinant DNA molecule according to claim 10 characterized in that the expression control sequence is selected from the group consisting of the E. coli lac system, the E. coli trp system, the major operator and promoter regions of phage λ, the control region of Filamenteous single-stranded DNA phages, the β-lactamase system of E. coli plasmids or other sequences which control the expression of genes of prokaryotic or eukaryotic cells and their viruses.
Claim 13
Dependent Claim
35 words
A recombinant DNA molecule according to claim 10 or 11, as those claims depend from claim 1, characterized in that it is selected from the group consisting of pFMDV-715, pFMDV-144, pFMDV-1034, pFMDV-1448, pFMDV-1824 and pFMDV-1933.
Claim 14
Dependent Claim
33 words
A recombinant DNA molecule according to claim 10 or 11, as those claims depend from claim 2, characterized in that it is selected from the group consisting of pPL-VP1-1, pPL-VPl-5, pFMDV-1034-Bal and pFMDV-1034-Bal-l(EcoRI-HindIII).
Claim 15
Dependent Claim
31 words
A recombinant DNA molecule according to claim 10 or 11 as those claims depend from claim 8, characterized in that it is selected from the group consisting of pFMDV-703 and pFMDV-331.
Claim 16
Dependent Claim
19 words
A host transformed with at least one recombinant DNA molecule according to any one of claims 9 to 14.
Claim 17
Dependent Claim
39 words
A host according to claim 15 characterized in that it is selected from the group consisting of strains of E. coli, Pseudomonas, Bacillus subtilis, Bacillus stearothermophilus, other bacilli, yeasts, other fungi, animal and plant hosts and human tissue cells.
Claim 18
Dependent Claim
55 words
A transformed host according to claim 15 or 16, as those claims depend from claim 12, characterized in that it is selected from the group consisting of E. coli HB101 (pBR322(Pst)/FMDV-715), E. coli HB101 (pBR322(Pst)/FMDV-144), E. coli HB1301 (pBR322(Pst)/ EMDV-1034), E. coli HB101 ( P BR322(Pst)/FMDV-1448), E. coli HB101 (pBR322(Pst)/FMDV-1824) and E. coli HB101 (pBR322(Pst)/FMDV-1933).
Claim 19
Dependent Claim
56 words
A transformed host according to claim 15 or 16, as those claims depend from claim 13 characterized in that it is selected from the group consisting of E. coli NFl (λN - cro - cI ts -pPL-VP1-1), E. coli M5219 (λN + cro - cI ts -pPL-VP1-1), E. coli W6(λ rex -pPL-VP1-5), [add 1034-Bal, 1034-Bal-1 (EcoRI-HindIII).
Claim 20
Dependent Claim
35 words
A transformed host according to claim 15 or 16, as those claims depend from.claim 14, characterized in that it is selected from the group consisting of E. coli HB101 (pBR322(Pst)/FMDV-703) and E. coli HB101 (pBR322(Pst)/FMDV-331).
Claim 21
Dependent Claim
29 words
A polypeptide or fragment or derivative thereof displaying the antigenicity of FMD viral antigens and produced by the transformed host according to any one of claims 15 to 19.
Claim 22
Dependent Claim
22 words
A polypeptide characterized in that it is coded for by a DNA sequence according to any one of claims 1 to 8.
Claim 23
Dependent Claim
36 words
A polypeptide according to claim 20 or 21 characterized in that the FMD viral antigens are selected from the group of antigens to FMDV serotypes O, A, C, SAT1, SAT2, SAT3, Asian I and combinations thereof.
Claim 24
Dependent Claim
51 words
A polypeptide according to claim 20 or 21 as those claims depend from claim 17, characterized in that at least a portion of it is selected from the group consisting of FMDV-715, FMDV-144, FMDV-1034, FMDV-1448, FMDV-1824, FMDV-1933 and fragments and derivatives thereof, said polypeptide displaying the antigenicity of FMD viral antigens.
Claim 25
Dependent Claim
50 words
A polypeptide according to claim 20 or 21 as those claims depend from claim 18, characterized in that at least a portion of it is selected from the group consisting of VP-1, VP1-1, VP1-5, FMDV-1034-Bal, FMDV-1034-Bal-l(EcoRI-HindIII), and fragments and derivatives thereof, said polypeptide displaying the antigencity of FMD viral antigens.
Claim 26
Dependent Claim
39 words
A polypeptide according to claim 24 characterized in that at least a portion of it is selected from polypeptides of the group consisting of LEU and fragments and derivatives thereof, said polypeptide displaying the antigenicity of FMD viral antigens.
Claim 27
Dependent Claim
51 words
A polypeptide according to claim 23 characterized in that at best a portion of it is selected from polypeptides of the group consisting of AspGlyTyr GlyGlyLeuValThrThrAspProLysThrAlaAspProValTyrGlyLysVal PheAsnProProArgAsnGlnLeuProGlyArgPheThrAsnLeuLeuAspVal AlaGluAlaCysProThrPheLeuArgPheGluGlyGlyValProTyrValThr ThrLysThrAspSerAspThrLeuLeuAlaGlnPheAspMetSerLeuAlaAla LysGlnMetSerAsnThrPheLeuAlaGlyLeuAlaGlnTyrTyrThrGlnTyr SerGlyThrIleAsnLeuHisPheMet(?)ThrGlyProThrAspAlaLysAla ArgTyrMetValAlaTyrAlaProLeuGlyMetGluProProLysThrProGlu AlaAlaAlaHisCysIleHisAlaGluTrpAspThrGlyLeuAsnSerLysPhe ThrPheSerIleProTyrLeuSerAlaAlaAspTyrAlaTyrThrAlaSerGly ValAlaGluThrThrAsnValGlnGlyTrpValCysLeuPheGlnIleThrHis GlyLysAlaAspGlyAspAlaLeuValValLeuAlaSerAlaGlyLysAspPhe GluLeuArgLeuProValAspAlaArgAlaGlu and fragments and derivatives thereof, said polypeptide displaying the antigenicity of FMD viral antigens.
Claim 28
Dependent Claim
47 words
A polypeptide according to claim 20 or 21 as those claims depend from claim 19, characterized in that at least a portion of it is selected from the group consisting of FMDV-703, FMDV-331 and fragments and derivatives thereof, said polypeptide displaying the antigenicity of FMD viral antigens.
Claim 29
Independent Claim
30 words
A method for producing a recombinant DNA molecule characterized by the step of introducing into a cloning vehicle a DNA sequence according to any one of claims 1 to 8.
Claim 30
Dependent Claim
48 words
A method according to claim 27 characterized by the additional step of introducing into said cloning vehicle an expression control sequence according to claim 11, said expression control sequence being introduced into said cloning vehicle so as to control and to regulate the expression of said DNA sequence.
Claim 31
Independent Claim
28 words
A method for transforming a host characterized by the step of introducing into a host a recombinant DNA molecule according to any one of claims 9 to 14.
Claim 32
Independent Claim
42 words
A method for producing a polypeptide displaying the specificity of FMD viral antigens comprising the steps of transforming an appropriate host with a recombinant DNA molecule according to any one of claims 10 to 14; culturing said host; and collecting said polypeptide.
Claim 33
Dependent Claim
39 words
The method according to claim 31, characterized in that the host is selected from the group consisting of strains of E. coli, Pseudomonas, Bacillus subtilis, Bacillus stearothermophilus, other bacilli, yeasts, fungi, animal or plant hosts, and human tissue cells.
Claim 34
Independent Claim
39 words
A method for producing a polypeptide displaying the specificity of FMD viral antigens comprising the steps of culturing a host transformed by a recombinant DNA molecule according to any one of claims 10 to 14 and collecting said polypeptide.
Claim 35
Dependent Claim
50 words
A process for selecting a DNA sequence coding for a polypeptide displaying the specificity of FMD viral antigens from a group of DNA sequences, characterized by the step of screening the DNA sequences to determine which hybridize to the DNA sequences according to any one of claims 1 to 8.
Claim 36
Dependent Claim
47 words
The process of claim 34 characterized in that the DNA sequence screened is selected from the group consisting of DNA sequences from natural sources, synthetic DNA sequences, DNA sequences from recombinant DNA molecules and DNA sequences which are a combination of any of the foregoing DNA sequences.
Claim 37
Dependent Claim
37 words
The process of claim 34 or 35 characterized in that the DNA sequence screened is selected from the group consisting of cDNA sequences from RNA of FMDV type 0, A, C, SAT1, SAT2, SAT3 and Asian I.
Claim 38
Dependent Claim
69 words
The process of any one of claims 34 to 36, as they depend from claim 3, characterized by the further step of using the hybridized DNA sequence as a primer either to permit at least a portion of the adjacent unhybridized portion of the DNA to be transcribed by reverse transcriptase or to permit at least a portion of the adjacent unhybridized portion of the DNA to be sequenced.
Claim 39
Dependent Claim
28 words
A composition for rendering cloven-footed animals resistant for at least some time to RMDV comprising at least one polypeptide according to any one of claims 20 to 27.
Claim 40
Dependent Claim
16 words
A composition according to claim 38 further characterized in that it comprises a pharmaceutically acceptable carrier.
Claim 41
Dependent Claim
34 words
A method of treating cloven-footed animals to render them resistant for at least some time to FMDV comprising treating them in a pharmaceutically acceptable manner with a composition according to claim 38 or 39.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.